马萨诸塞州剑桥市 - Sarepta Therapeutics (NASDAQ: SRPT) 公布的第四季度业绩超出分析师预期，但由于投资者关注其支出增加，股价下跌4.6%。 这家生物制药公司调整后每股收益达到USD 1.90，超过分析师一致预期的USD 1.54。营收同比增长66%至USD 658.4 million，同样高于预期的USD 589.45 million。

英为财情Investing.com - Sarepta Therapeutics (NASDAQ: SRPT )星期三发布了第四季度的财报，数据显示，公司营收高于分析师的预期，每股收益超出了分析师的预期。

Operator Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% ...

Reports Q4 revenue $658.4M, consensus $631.03M. “2024 performance represented the fruition of our multi-year strategy to become a ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

The price trend for Sarepta Therapeutics (SRPT) has been bearish lately and the stock has lost 9% over the past four weeks.

CAMBRIDGE, Mass. - Sarepta Therapeutics (NASDAQ: SRPT) reported fourth quarter earnings that beat analyst expectations, but the stock fell 4.6% as investors focused on rising expenses.

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported fourth-quarter profit of $159 million. On a per-share basis, the Cambridge, Massachusetts-based ...

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...